{"log_id": 5328765228764370595, "direction": 0, "words_result_num": 45, "words_result": [{"probability": {"variance": 0.003685, "average": 0.979769, "min": 0.616477}, "location": {"width": 864, "top": 242, "height": 45, "left": 156}, "words": "4水痘:2岁以上儿童按体重一次20mg/kg,一日4次,共5日,出现症状立即开始治疗。40kg"}, {"probability": {"variance": 0.003877, "average": 0.984279, "min": 0.674883}, "location": {"width": 503, "top": 274, "height": 34, "left": 110}, "words": "以上儿童和成人常用量为一次0.8g,一日4次,共5日"}, {"probability": {"variance": 0.000147, "average": 0.996546, "min": 0.923299}, "location": {"width": 906, "top": 306, "height": 45, "left": 116}, "words": "【不良反应】偶有头晕、头痛、关节痛、恶心、呕吐、腹泻、胃部不适、食欲减退、口渴、白细胞"}, {"probability": {"variance": 0.000725, "average": 0.991773, "min": 0.840622}, "location": {"width": 776, "top": 338, "height": 38, "left": 111}, "words": "下降、蛋白尿及尿素氮轻度升高、皮肤瘙痒等,长程给药偶见痤疮、失眠、月经紊乱"}, {"probability": {"variance": 5e-06, "average": 0.998382, "min": 0.991648}, "location": {"width": 249, "top": 373, "height": 26, "left": 118}, "words": "【禁忌】对本品过敏者禁用"}, {"probability": {"variance": 1e-06, "average": 0.999105, "min": 0.997229}, "location": {"width": 113, "top": 405, "height": 23, "left": 118}, "words": "【注意事项】"}, {"probability": {"variance": 0.006175, "average": 0.972705, "min": 0.66754}, "location": {"width": 349, "top": 436, "height": 27, "left": 153}, "words": "1.对更昔洛韦过敏者也可能对本品过敏"}, {"probability": {"variance": 0.001206, "average": 0.98326, "min": 0.888215}, "location": {"width": 349, "top": 468, "height": 27, "left": 152}, "words": "2.脱水或已有肝、肾功能不全者需慎用"}, {"probability": {"variance": 0.000573, "average": 0.994293, "min": 0.847308}, "location": {"width": 876, "top": 496, "height": 44, "left": 148}, "words": "3.严重免疫功能缺陷者长期或多次应用本品治疗后可能引起单纯疱疹病毒和带状疱疹病毒对本"}, {"probability": {"variance": 0.002319, "average": 0.991223, "min": 0.687129}, "location": {"width": 858, "top": 530, "height": 39, "left": 114}, "words": "品耐药。如单纯疱疹患者应用阿昔洛韦后皮损不见改善者应测试单纯疱疹病毒对本品的敏感性"}, {"probability": {"variance": 0.004659, "average": 0.978408, "min": 0.635551}, "location": {"width": 875, "top": 560, "height": 42, "left": 150}, "words": "4.随访检查:由于生殖器疱疹患者大多易患子宫颈癌,因此患者至少应一年检查一次,以早期发"}, {"probability": {"variance": 0, "average": 0.999298, "min": 0.999298}, "location": {"width": 23, "top": 595, "height": 22, "left": 115}, "words": "现"}, {"probability": {"variance": 0.00013, "average": 0.994925, "min": 0.96009}, "location": {"width": 347, "top": 623, "height": 28, "left": 179}, "words": "一旦疱疹症状与体征出现,应尽早给药"}, {"probability": {"variance": 0.004655, "average": 0.978884, "min": 0.631065}, "location": {"width": 860, "top": 654, "height": 40, "left": 154}, "words": "6.进食对血药浓度影响不明显。但在给药期间应给予患者充足的水,防止本品在肾小管内沉淀"}, {"probability": {"variance": 0.00311, "average": 0.989239, "min": 0.637048}, "location": {"width": 848, "top": 684, "height": 38, "left": 177}, "words": "生殖器复发性疱疹感染以间歇短程疗法给药有效。由于动物实验曾发现本品对生育的影响及致"}, {"probability": {"variance": 0.007552, "average": 0.980619, "min": 0.467719}, "location": {"width": 875, "top": 715, "height": 37, "left": 117}, "words": "突变,因此口服剂量与疗程不应超过推荐标准.生殖器复发性疱疹的长程疗法也不应超过6个月"}, {"probability": {"variance": 0.034111, "average": 0.88192, "min": 0.513328}, "location": {"width": 91, "top": 705, "height": 39, "left": 1049}, "words": "药保监督管"}, {"probability": {"variance": 0.000573, "average": 0.991387, "min": 0.891561}, "location": {"width": 670, "top": 745, "height": 33, "left": 156}, "words": "8.一次血液透析可使血药浓度减低60%,因此血液透析后应补给一次剂量"}, {"probability": {"variance": 0.002807, "average": 0.987964, "min": 0.708443}, "location": {"width": 607, "top": 776, "height": 32, "left": 190}, "words": "本品对单纯疱疹病毒的潜伏感染和复发无明显效果,不能根除病毒"}, {"probability": {"variance": 0.001436, "average": 0.938833, "min": 0.900943}, "location": {"width": 79, "top": 752, "height": 47, "left": 1063}, "words": "缝章"}, {"probability": {"variance": 1e-06, "average": 0.998726, "min": 0.996314}, "location": {"width": 230, "top": 807, "height": 25, "left": 125}, "words": "【孕妇及哺乳期妇女用药】"}, {"probability": {"variance": 5.7e-05, "average": 0.996544, "min": 0.968278}, "location": {"width": 691, "top": 835, "height": 34, "left": 162}, "words": "药物能通过胎盘,虽动物实验证实对胚胎无影响,但孕妇用药仍需权衡利弊"}, {"probability": {"variance": 0.004914, "average": 0.977661, "min": 0.662821}, "location": {"width": 828, "top": 864, "height": 40, "left": 159}, "words": "药物在乳汁中的浓度为血药浓度的0.6~4.1倍,虽未发现婴儿异常,但哺乳期妇女应慎用"}, {"probability": {"variance": 9.1e-05, "average": 0.996895, "min": 0.957807}, "location": {"width": 368, "top": 896, "height": 29, "left": 125}, "words": "【儿童用药】2岁以下小儿剂量尚未确定"}, {"probability": {"variance": 0.006968, "average": 0.977829, "min": 0.549122}, "location": {"width": 631, "top": 927, "height": 32, "left": 126}, "words": "【老年用药】由于生理性肾功能的衰退,本品剂量与用药间期需调整"}, {"probability": {"variance": 5.2e-05, "average": 0.994639, "min": 0.97683}, "location": {"width": 153, "top": 960, "height": 25, "left": 127}, "words": "【药物相互作用】"}, {"probability": {"variance": 0.022198, "average": 0.941244, "min": 0.40825}, "location": {"width": 898, "top": 979, "height": 43, "left": 160}, "words": "1.与齐多夫 Zidovudine)合用可引起肾毒性,表现为深度昏睡和公司"}, {"probability": {"variance": 0.012828, "average": 0.950435, "min": 0.554461}, "location": {"width": 869, "top": 1019, "height": 37, "left": 161}, "words": "2.与丙磺舒竞争性抑制有机酸分泌,合并用丙磺舒可使本品的排泄减.衰期延长,体内药"}, {"probability": {"variance": 3e-06, "average": 0.99797, "min": 0.99614}, "location": {"width": 85, "top": 1051, "height": 23, "left": 123}, "words": "物量蓄积"}, {"probability": {"variance": 1e-05, "average": 0.99806, "min": 0.989072}, "location": {"width": 200, "top": 1082, "height": 25, "left": 129}, "words": "【药物过量】尚不明确"}, {"probability": {"variance": 0.000127, "average": 0.996372, "min": 0.928388}, "location": {"width": 878, "top": 1109, "height": 38, "left": 130}, "words": "【药理毒理】抗病毒药体外对单纯性疱疹病毒、水痘带状疱疹病毒、巨细胞病毒等具抑制作用"}, {"probability": {"variance": 0.003391, "average": 0.985009, "min": 0.62203}, "location": {"width": 869, "top": 1143, "height": 38, "left": 166}, "words": "本品进入疱疹病毒感染的细胞后,与脱氧核苷竞争病毒胸苷激酶或细胞激酶,药物被磷酸化成活"}, {"probability": {"variance": 0.002744, "average": 0.979151, "min": 0.75401}, "location": {"width": 899, "top": 1170, "height": 41, "left": 126}, "words": "化型阿昔洛韦三磷酸酯,然后通过二种方式抑制病毒复制:①干扰病毒DNA多聚酶,抑制病毒的复制"}, {"probability": {"variance": 0.000954, "average": 0.990439, "min": 0.819028}, "location": {"width": 647, "top": 1206, "height": 27, "left": 127}, "words": "②在DNA多聚酶作用下,与增长的DNA链结合,引起DNA链的延伸中断"}, {"probability": {"variance": 0.016773, "average": 0.965318, "min": 0.381107}, "location": {"width": 868, "top": 1233, "height": 41, "left": 167}, "words": "本品对病毒有特殊的亲和力,但对哺乳动物宿主细胞毒性低体外细胞转化测定有致癌报道但"}, {"probability": {"variance": 0.001278, "average": 0.989816, "min": 0.813562}, "location": {"width": 907, "top": 1266, "height": 39, "left": 128}, "words": "动物实验未见致癌依据。某些动物实验显示高浓度药物可致突变,但无染色体改变的依据。本品的致"}, {"probability": {"variance": 0.002337, "average": 0.984489, "min": 0.744043}, "location": {"width": 909, "top": 1298, "height": 41, "left": 127}, "words": "癌与致突变作用尚不明确。大剂量注射可致动物睾丸萎缩和精子数减少,药物能通过胎盘动物实验证"}, {"probability": {"variance": 0.000297, "average": 0.99126, "min": 0.949354}, "location": {"width": 144, "top": 1333, "height": 26, "left": 130}, "words": "实对胚胎无影响"}, {"probability": {"variance": 0.016326, "average": 0.963104, "min": 0.406427}, "location": {"width": 900, "top": 1361, "height": 40, "left": 136}, "words": "【药代动力学】口服吸收差,约15%~30%由胃肠道吸收.进食对血药浓度影响不明显能广泛分布"}, {"probability": {"variance": 0.001803, "average": 0.990954, "min": 0.714396}, "location": {"width": 905, "top": 1393, "height": 39, "left": 131}, "words": "至各组织与体液中,包括脑、肾、肺、肝、小肠、肌肉、脾、乳汁、子宫、阴道粘膜与分泌物、脑脊"}, {"probability": {"variance": 0.000979, "average": 0.990312, "min": 0.811384}, "location": {"width": 911, "top": 1426, "height": 40, "left": 130}, "words": "液及疱疹液。在肾、肝和小肠中浓度高,脑脊液中浓度约为血中浓度的一半。药物可通过胎盘。每4"}, {"probability": {"variance": 0.004968, "average": 0.964493, "min": 0.672735}, "location": {"width": 911, "top": 1456, "height": 43, "left": 129}, "words": "小时口服200mg和400mg,5天后的血药峰浓度(C)分别为0.6mg/L和1.2mg/L。本品蛋白结合率低"}, {"probability": {"variance": 0.020951, "average": 0.941726, "min": 0.413579}, "location": {"width": 904, "top": 1490, "height": 39, "left": 138}, "words": "(9%~33%)。在肝内代谢,主要代谢物占给药量的9%~14%,经尿排泄。血消除半衰期(ta)约为"}, {"probability": {"variance": 0.000848, "average": 0.987635, "min": 0.860865}, "location": {"width": 906, "top": 1518, "height": 41, "left": 133}, "words": "25小时。肌酐清除率50~80ml/分钟和15~50ml/分钟时,血消除半衰期(tp)分别为3.0小时和"}, {"probability": {"variance": 0.007219, "average": 0.972938, "min": 0.558483}, "location": {"width": 908, "top": 1549, "height": 41, "left": 132}, "words": "35小时无尿者的血消除半衰期(tuas)长达19.5小时,血液透析时降为5.7小时本品主要经肾"}], "language": 3}